

TAVFLOX

Levofloxacin 500mg

**THE POWER IN
TREATING
RESPIRATORY
INFECTIONS**



 **Avalon** Pharma

TAVFLOX

Levofloxacin 500mg

To The Point

Tavflox shows high coverage, high clinical success against most of upper and lower respiratory tract infections (1,2,3,4,5)

Highest coverage against (Gm +ve, Gm-ve, Atypical) bacteria causing respiratory infections
1,2

High clinical success in treatment of AECB, Community acquired pneumonia & acute bacterial sinusitis
3,4,5

TAVFLOX
(LEVOFLOXACIN)
500

Higher tolerability than Moxifloxacin & Gemifloxacin
6

- **TAVFLOX 500mg** is active against more than 99% of isolates of S pneumoniae, even those resistant to penicillin¹
- **TAVFLOX (Levofloxacin 500)** showed 97% susceptibility against most of microorganisms causing AECB and pneumoniae in comparison to 89% for Amoxicillin clavulanate and 89% for Azithromycin⁷

Indication	Daily Dosage regimen (According to severity)	Duration of treatment (According to severity)
Acute bacterial sinusitis	500 mg once daily	10 - 14 days
Acute bacterial exacerbations of chronic bronchitis (AECB)	500 mg once daily	7 - 10 days
Community acquired pneumoniae	500 mg once or twice daily	7 - 14 days

 **Avalon Pharma**

Middle East Pharmaceutical Industries Co. Ltd.
P.O. Box 301332 Riyadh 11372
Tel: +966 11 464 3924
Fax: +966 11 462 0471
Email: info@avalon.com.sa avalonpharmaceutical.com

1. FDA approval of Ilevo, Moxi,Cipro, Azithro and Amox clav, www.FDA.ORG, FEB 2009

2. International journal of antimicrobial agents 285 (2006) S 115-5127

3. Urueta - Robledo J, Ariza H,Jardim caballero A,Garcia-calderson A,Amabile-Cuevas CF, Hernandez-oliva G, Vivar-Orozco R; Mox-CB study group .Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: The latin American cohort, Respir Med, 2006 sep; 100 (9): 1504-11

4. Frank, Ellioh; Liu jing; Kinasewitz, Gary; Moran, Gregory J; Oros, Margaret P, Olson , William H; Reichi, Veronica, Freitag, Susan, Bahal,Neeelam, Wiesing Barbara A (2002) U.S. Department of veterans affairs staff publications 51, <http://digital commons.unl.edu>

5. Gehanno P, Pessey JJ, Serrano E

6. Using safety profile to differentiate between the newer fluoroquinolones Keith A, Rovold, pharm, D, FCP, FCCP

7. Journal of antimicrobial chemotherapy Volume 43, Issue suppl_3, 1 June 1999, Pages 37-42, https://doi.org/10.1093/Jac43.suppl_3.37